DNA logo

Ginkgo Bioworks Holdings Inc. (DNA)$8.41

Market Cap: 402.39 MCurrency: USD

Research Snapshot

Static fundamentals, valuation context, and investor signals for Ginkgo Bioworks Holdings Inc. (DNA).

HEALTHCARE
BIOTECHNOLOGY
DCF ready

Valuation

-1.3x

EV/FCF, N/A FCF yield

Quality

-0.1%

ROIC, -105.0% FCF margin

Growth

17.3%

5Y sales (revenue) CAGR

Balance sheet

0.0x

Debt/equity, 4.9x current ratio

Superinvestors

1

Top: Viking Global Investors (0.1%)

Strengths to research

  • Revenue compounded at 17.3% over five years.
  • Debt/equity looks manageable at 0.0x.

Watchouts

  • Free cash flow margin is negative at -105.0%.
Annual data: 7 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026

Quality Scorecard

Build-time composite score for DNA.

Grade F
22
/ 100

Peer Comparison

Target stock against 8 market-cap comparable peers.

Heat map: red worst to green best
DNA
Target
Ginkgo Bioworks Holdings Inc.$402.4M-1.5x-1.3x-0.1%17.3%-105.0%N/AN/AN/A
ORICORIC Pharmaceuticals Inc.$405.2M-5.7x-3.2x-33.7%N/AN/AN/AN/AN/A
PGENPrecigen Inc.$448.7M-3.1x-5.7x-219.7%-21.3%-927.6%N/AN/AN/A
TRVITrevi Therapeutics Inc.$667.1M-44.2x-15.4x-23.3%N/AN/AN/AN/AN/A
NUVBNuvation Bio Inc.$808.4M-7.9x-4.0x-58.0%N/A-275.7%N/AN/AN/A
RCKTRocket Pharmaceuticals Inc.$838.3M-1.5x-4.0x-80.5%N/AN/AN/AN/AN/A
INBXInhibrx$178.5M-11.2x-0.4x-1752.2%N/A-9986.5%N/AN/AN/A
DMACDiaMedica Therapeutics Inc.$171.4MN/A-5.4x-58.4%N/AN/AN/AN/AN/A
PHVSPharvaris NV$1.0BN/AN/AN/AN/AN/AN/AN/AN/A

Financial Charts

No financial data available for DNA (annual).

1 superinvestors own DNA

Current quarter ownership and quarter-over-quarter share changes.

Superinvestor ownership
FundSharesValue% PortfolioQoQ Change
Viking Global Investors

Viking Global Investors

3,577,128$22M0.06%0.0%